Calcitonin-Salmon
Also referenced as: Salmon calcitonin
A calcitonin analogue that suppresses bone resorption.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved indications differ by formulation: injectable products include hypercalcemia, symptomatic Paget disease and selected postmenopausal osteoporosis; nasal products are narrower.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A calcitonin analogue that suppresses bone resorption.
FDA-approved indications differ by formulation: injectable products include hypercalcemia, symptomatic Paget disease and selected postmenopausal osteoporosis; nasal products are narrower.
Injectable and nasal products have different indications; the molecule is not a general bone-health supplement.
Why It's Being Studied
- Hypercalcemia
- Paget disease
- Selected osteoporosis
Mechanism of Action
Calcitonin-receptor signalling reduces osteoclast activity and can lower serum calcium.
Calcitonin-receptor signalling reduces osteoclast activity and can lower serum calcium. Injectable and nasal products have different indications; the molecule is not a general bone-health supplement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Hypercalcemia
- Paget disease
- Selected osteoporosis
- Approved injectable products
- Approved nasal products
Evidence Summary
Human evidence supports formulation-specific indications, but fracture-efficacy evidence is limited relative to some other osteoporosis therapies.
Higher tiers carry more weight. Filled tiers have evidence for Calcitonin-Salmon; tap to read it.
- Human evidence supports formulation-specific indications, but fracture-efficacy evidence is limited relative to some other osteoporosis therapies.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human evidence supports formulation-specific indications, but fracture-efficacy evidence is limited relative to some other osteoporosis therapies.
Reported Adverse Events in Research
- Hypocalcemia, serious allergy and a possible malignancy association constrain interpretation.
Limitations of Current Evidence
- Injectable and nasal products have different indications; the molecule is not a general bone-health supplement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Calcitonin-Salmon | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Approved injectable products, Approved nasal products | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Calcitonin-Salmon — prescribing label